DGAP-News: Epigenomics AG / Key word(s): Study results/Study02.12.2019 / 11:37 The issuer is solely responsible for the content of this announcement. Epigenomics AG Reports on New Micro-Simulation Study Results Published in Cancer Medicine Indicating That Epi proColon Provides Clinically Meaningful Reductions in Incidence and Mortality of Colorectal Cancer Adherence rates and screening intervals recognized as […]
Year: 2019
02. December 2019
Epigenomics AG: Epigenomics AG Reports on New Micro-Simulation Study Results Published in Cancer Medicine Indicating That Epi proColon Provides Clinically Meaningful Reductions in Incidence and Mortality of Colorectal Cancer
Read more
29. November 2019
Epigenomics AG: New Micro-Simulation Study in Cancer Medicine Finds Epi proColon(R) Provides Clinically Meaningful Reductions in Incidence and Mortality of Colorectal Cancer
DGAP-News: Epigenomics AG / Key word(s): Study results/Study29.11.2019 / 15:00 The issuer is solely responsible for the content of this announcement. New Micro-Simulation Study in Cancer Medicine Finds Epi proColon(R) Provides Clinically Meaningful Reductions in Incidence and Mortality of Colorectal Cancer Adherence rates and screening intervals recognized as decisive elements of successful screening strategies Berlin […]
26. November 2019
Epigenomics AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
Epigenomics AG26.11.2019 / 11:38 Veröffentlichung einer Stimmrechtsmitteilung übermittelt durch DGAP – ein Service der EQS Group AG.Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Stimmrechtsmitteilung 1. Angaben zum Emittenten Name: Epigenomics AG Straße, Hausnr.: Geneststraße 5 PLZ: 10829 Ort: BerlinDeutschland Legal Entity Identifier (LEI): 549300X1C4U862NDLN97 2. Grund der Mitteilung Erwerb bzw. […]
19. November 2019
Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Epigenomics AG19.11.2019 / 11:34 Dissemination of a Voting Rights Announcement transmitted by DGAP – a service of EQS Group AG.The issuer is solely responsible for the content of this announcement. Notification of Major Holdings 1. Details of issuer Name: Epigenomics AG Street: Geneststraße 5 Postal code: 10829 City: BerlinGermany Legal Entity Identifier (LEI): 549300X1C4U862NDLN97 2. […]
19. November 2019
Epigenomics AG: Korrektur einer Veröffentlichung vom 15.11.2019 gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
Epigenomics AG19.11.2019 / 11:31 Veröffentlichung einer Stimmrechtsmitteilung übermittelt durch DGAP – ein Service der EQS Group AG.Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Stimmrechtsmitteilung 1. Angaben zum Emittenten Name: Epigenomics AG Straße, Hausnr.: Geneststraße 5 PLZ: 10829 Ort: BerlinDeutschland Legal Entity Identifier (LEI): 549300X1C4U862NDLN97 2. Grund der Mitteilung X Erwerb bzw. […]
19. November 2019
Epigenomics AG Reports Financial Results for the First Nine Months 2019
DGAP-News: Epigenomics AG / Key word(s): Quarterly / Interim Statement/9 Month figures19.11.2019 / 08:00 The issuer is solely responsible for the content of this announcement. Epigenomics AG Reports Financial Results for the First Nine Months 2019 Berlin (Germany) and San Diego, CA (USA), November 19, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the “Company”) […]